(function(){var loadHandler=window['sl_{5C8B7C35-DAA8-4401-9B1E-7424B0746284}'];loadHandler&&loadHandler(35, '<div id="spr0_3ab4975"><div id="spr1_3ab4975" class="kern slide"><img id="img6_3ab4975" src="data/img16.png" width="1280px" height="720px" alt="" style="left:0px;top:0px;"/><div id="spr3_3ab4975"><img id="img0_3ab4975" src="data/img0.png" width="1279.5" height="720.75" alt="hashOverlay-FullResolve.png" style="left:0.188px;top:-0.281px;"/></div><div id="spr4_3ab4975" style="left:0px;top:206.849px;"><img id="img1_3ab4975" src="data/img17.png" width="1095.75" height="34.5" alt="HD-ShadowLong.png" style="left:0.031px;top:-0.293px;"/></div><div id="spr5_3ab4975" style="left:1111.373px;top:206.954px;"><img id="img2_3ab4975" src="data/img13.png" width="168" height="15.75" alt="HD-ShadowShort.png" style="left:0.11px;top:-0.226px;"/></div><div id="svg0_3ab4975" style="top:64px;"><svg width="1096" height="144" viewBox="0 0 1096 144"><path fill="#262626" d="M0,0 h1095.833 v143.643 h-1095.833 Z"/></svg></div><div id="svg1_3ab4975" style="left:1111.373px;top:64px;"><svg width="169" height="144" viewBox="0 0 169 144"><path fill="#f09415" d="M0,0 h168.294 v143.643 h-168.294 Z"/></svg></div></div><div id="spr2_3ab4975" class="kern slide"><img id="img3_3ab4975" src="data/img41.png" width="1279.667" height="720" alt=""/><div id="spr6_3ab4975"><img id="img4_3ab4975" src="data/img0.png" width="1279.5" height="720.75" alt="" style="left:0.188px;top:-0.281px;"/></div><div id="svg3_3ab4975" style="left:487.614px;"><svg width="793" height="721" viewBox="0 0 793 721"><path fill="#f09415" d="M0,0 h792.96 v720 h-792.96 Z"/></svg></div><div id="spr7_3ab4975" style="left:0px;top:525.569px;"><img id="img5_3ab4975" src="data/img42.png" width="521.25" height="15.75" alt="" style="left:0.011px;top:-0.211px;"/></div><div id="svg4_3ab4975" style="left:-0px;top:193.046px;"><svg width="522" height="334" viewBox="0 0 522 334"><path fill="#262626" d="M0,0 h521.214 v333.908 h-521.214 Z"/></svg></div><div id="spr8_3ab4975" style="left:71.425px;top:216.615px;"><div style="width:0px;"><span id="txt0_3ab4975" data-width="213.730469" style="left:177.047px;top:24.433px;">RCTs, RWE,</span></div><div style="width:0px;"><span id="txt1_3ab4975" data-width="368.669922" style="left:14.933px;top:69.073px;">surrogate variables:</span></div><div style="width:0px;"><span id="txt2_3ab4975" data-width="125.271477" style="left:257.6px;top:113.713px;">Ethics,</span></div><div style="width:0px;"><span id="txt3_3ab4975" data-width="321.665344" style="left:61.433px;top:158.353px;">acceptability and</span></div><div style="width:0px;"><span id="txt4_3ab4975" data-width="183.618484" style="left:199.433px;top:202.993px;">feasibility</span></div></div><div id="spr9_3ab4975" style="left:555.17px;top:69.407px;"><div style="width:0px;"><span id="txt5_3ab4975" class="nokern relpos" dir="auto" style="left:9.6px;top:87.514px;">•</span> <span id="txt6_3ab4975" class="relpos" data-width="513.736938" style="left:24.264px;top:87.052px;">Differences in regulation, i.e., devices and</span></div><div style="width:0px;"><span id="txt7_3ab4975" data-width="237.747391" style="left:33.6px;top:115.852px;">medicinal products.</span></div><div style="width:0px;"><span id="txt8_3ab4975" class="nokern relpos" dir="auto" style="left:9.6px;top:157.74px;">•</span> <span id="txt9_3ab4975" class="relpos" data-width="604.986938" style="left:24.264px;top:157.277px;">Lower acceptability of RWD where the outcome of</span></div><div style="width:0px;"><span id="txt10_3ab4975" data-width="405.729156" style="left:33.6px;top:186.786px;">interest is efficacy/effectiveness.</span></div><div style="width:0px;"><span id="txt11_3ab4975" class="nokern relpos" dir="auto" style="left:9.6px;top:228.673px;">•</span> <span id="txt12_3ab4975" class="relpos" data-width="518.072876" style="left:24.264px;top:228.211px;">Positive regulatory decisions v. coverage v.</span></div><div style="width:0px;"><span id="txt13_3ab4975" data-width="191.393219" style="left:33.6px;top:257.719px;">reimbursement.</span></div><div style="width:0px;"><span id="txt14_3ab4975" class="nokern relpos" dir="auto" style="left:9.6px;top:299.606px;">•</span> <span id="txt15_3ab4975" class="relpos" data-width="565.559875" style="left:24.264px;top:299.144px;">Benefit/risk (B/R) aspects (need of estimate of</span></div><div style="width:0px;"><span id="txt16_3ab4975" data-width="546.940063" style="left:33.6px;top:328.652px;">efficacy free from the biases of observational</span></div><div style="width:0px;"><span id="txt17_3ab4975" data-width="582.174438" style="left:33.6px;top:357.452px;">data, but also need for continuous monitoring of</span></div><div style="width:0px;"><span id="txt18_3ab4975" data-width="277.747375" style="left:33.6px;top:386.252px;">the ever-changing B/R.</span></div><div style="width:0px;"><span id="txt19_3ab4975" class="nokern relpos" dir="auto" style="left:9.6px;top:428.14px;">•</span> <span id="txt20_3ab4975" class="relpos" data-width="596.080688" style="left:24.264px;top:427.677px;">Cases where traditional RCT may be unfeasible or</span></div><div style="width:0px;"><span id="txt21_3ab4975" data-width="121.302078" style="left:33.6px;top:457.186px;">unethical.</span></div></div></div></div>', '{"s":[]}');})();